tiprankstipranks
Trending News
More News >
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
US Market
Advertisement

60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Statistics & Valuation Metrics

Compare
184 Followers

Total Valuation

60 Degrees Pharmaceuticals, Inc. has a market cap or net worth of $5.79M. The enterprise value is $11.16M.
Market Cap$5.79M
Enterprise Value$11.16M

Share Statistics

60 Degrees Pharmaceuticals, Inc. has 4,104,469 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,104,469
Owned by Insiders2.05%
Owned by Institutions<0.01%

Financial Efficiency

60 Degrees Pharmaceuticals, Inc.’s return on equity (ROE) is -1.97 and return on invested capital (ROIC) is -236.33%.
Return on Equity (ROE)-1.97
Return on Assets (ROA)-1.38
Return on Invested Capital (ROIC)-236.33%
Return on Capital Employed (ROCE)-2.37
Revenue Per Employee227.12K
Profits Per Employee-2.65M
Employee Count3
Asset Turnover0.12
Inventory Turnover0.87

Valuation Ratios

The current PE Ratio of 60 Degrees Pharmaceuticals, Inc. is ―. 60 Degrees Pharmaceuticals, Inc.’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.73
Price to FCF
Price to Operating Cash Flow-0.58
PEG Ratio

Income Statement

In the last 12 months, 60 Degrees Pharmaceuticals, Inc. had revenue of 681.35K and earned -7.95M in profits. Earnings per share was -18.55.
Revenue681.35K
Gross Profit222.81K
Operating Income-9.71M
Pretax Income-7.96M
Net Income-7.95M
EBITDA-7.88M
Earnings Per Share (EPS)-18.55

Cash Flow

In the last 12 months, operating cash flow was -3.32M and capital expenditures -40.74K, giving a free cash flow of -3.36M billion.
Operating Cash Flow-3.32M
Free Cash Flow-3.36M
Free Cash Flow per Share-0.82

Dividends & Yields

60 Degrees Pharmaceuticals, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.35
52-Week Price Change-79.27%
50-Day Moving Average1.66
200-Day Moving Average3.08
Relative Strength Index (RSI)50.82
Average Volume (3m)127.44K

Important Dates

60 Degrees Pharmaceuticals, Inc. upcoming earnings date is Nov 13, 2025, During Market Hours (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 13, 2025
Ex-Dividend Date

Financial Position

60 Degrees Pharmaceuticals, Inc. as a current ratio of 3.25, with Debt / Equity ratio of 6.35%
Current Ratio3.25
Quick Ratio2.98
Debt to Market Cap0.05
Net Debt to EBITDA0.19
Interest Coverage Ratio-1.23K

Taxes

In the past 12 months, 60 Degrees Pharmaceuticals, Inc. has paid 250.00 in taxes.
Income Tax250.00
Effective Tax Rate>-0.01

Enterprise Valuation

60 Degrees Pharmaceuticals, Inc. EV to EBITDA ratio is -0.18, with an EV/FCF ratio of -0.25.
EV to Sales2.10
EV to EBITDA-0.18
EV to Free Cash Flow-0.25
EV to Operating Cash Flow-0.25

Balance Sheet

60 Degrees Pharmaceuticals, Inc. has $1.97M in cash and marketable securities with $154.25K in debt, giving a net cash position of -$1.81M billion.
Cash & Marketable Securities$1.97M
Total Debt$154.25K
Net Cash-$1.81M
Net Cash Per Share-$0.44
Tangible Book Value Per Share$8.35

Margins

Gross margin is 28.88%, with operating margin of -1425.85%, and net profit margin of -1166.39%.
Gross Margin28.88%
Operating Margin-1425.85%
Pretax Margin-1167.60%
Net Profit Margin-1166.39%
EBITDA Margin-1157.09%
EBIT Margin-1166.44%

Analyst Forecast

The average price target for 60 Degrees Pharmaceuticals, Inc. is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside392.96% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast120.67%
EPS Growth Forecast-456.33%

Scores

Smart ScoreN/A
AI Score38.6
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis